Evidence map›Paper›PMID 34725177›Full record

ArticleThe Journal of rheumatology2022

Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement.

Alfredo Aguirre, Jinoos Yazdany

Open access · bronzeAbstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Alfredo AguirreA. Aguirre, MD, Clinical Fellow, J. Yazdany, MD, MPH, Professor, Division of Rheumatology, University of California, San Francisco, California, USA. alfredo.aguirre@ucsf.edu.ORCID 0000-0001-6999-6297
Jinoos YazdanyA. Aguirre, MD, Clinical Fellow, J. Yazdany, MD, MPH, Professor, Division of Rheumatology, University of California, San Francisco, California, USA.ORCID 0000-0002-3508-4094
University of California, San Francisco · US

Funding

RESOURCE-BASED CENTER FOR THE ADVANCEMENT OF PRECISION MEDICINE IN RHEUMATOLOGYP30AR070155 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mary C Nakamura · 2016 to 2026
$8.2M
Academic Rheumatology and Clinical ImmunologyT32AR079068 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jinoos Yazdany, JULIE ZIKHERMAN · 2021 to 2026
$2.5M
Advancing Quality and Outcomes Measurement in RheumatologyK24AR074534 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jinoos Yazdany · 2019 to 2026
$1.5M
NIAMS NIH HHS K24 AR074534NIAMS NIH HHS P30 AR070155NIAMS NIH HHS T32 AR079068
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidBiological ProductsHepatitis BHumansAntirheumatic AgentsBiological Products

Identifiers

PMID34725177
PMCPMC9068232
OpenAlexW3211164941

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.